Welcome to our dedicated page for Insulet Corporation news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet Corporation stock.
Insulet Corporation (symbol: PODD) is a pioneering medical device company headquartered in Billerica, Massachusetts. Founded in 2000, the company is dedicated to improving the lives of people with diabetes through its innovative Omnipod Insulin Management System. The Omnipod system revolutionizes insulin pump therapy by making it more accessible and user-friendly compared to traditional methods.
The Omnipod system offers several advantages over multiple daily insulin injections (MDI), including better glycemic control, fewer hypoglycemic events, reduced glycemic variability, and improved quality of life. Despite these benefits, the complexity, cost, and inconvenience of conventional insulin pump technology have deterred many from adopting pump therapy. Insulet's Omnipod addresses these challenges by providing a discreet, tubeless, and easy-to-use system that automates the process and ensures virtually pain-free insertion. The system consists of only two parts that communicate wirelessly, streamlining the user experience.
Since its approval by the U.S. Food and Drug Administration in 2005, the Omnipod has been adopted by approximately 425,000 insulin-dependent diabetics worldwide. This level of adoption underscores the effectiveness and user satisfaction associated with Insulet's flagship product. The Omnipod is notable for its disposable, smartphone-controlled insulin infusion device, which enhances the convenience and flexibility of insulin therapy.
Insulet continues to innovate and expand its product offerings. The company is currently engaged in multiple projects aimed at further improving diabetes management and enhancing the quality of life for its users. Financially, Insulet maintains a strong position, driven by robust sales growth and strategic partnerships that support its mission.
Overall, Insulet Corporation stands out in the medical device industry for its commitment to innovation and its impact on the diabetes community. Investors and stakeholders can expect continued advancements and a strong financial performance as the company pursues its mission to simplify and improve insulin management.
Insulet (NASDAQ: PODD) reported preliminary Q2 2024 revenue results, showcasing strong performance. Total revenue reached $488 million, up 23% year-over-year, exceeding the company's guidance of 15% to 18% growth in constant currency. The growth was driven by robust demand for Omnipod 5, with Total Omnipod revenue increasing by 26% to $480 million. U.S. Omnipod revenue grew 27% to $352 million, while International Omnipod revenue rose 23% to $128 million. Based on these results, Insulet plans to raise its full-year 2024 Total Omnipod revenue outlook to 18% to 21% growth, up from the previous 15% to 19% range. The company will release full Q2 2024 financial results on August 8, 2024.
Imperative Care, a medical technology company focused on stroke and ischemic diseases, has announced the initial closing of an oversubscribed Series E financing led by Ally Bridge Group. The financing, which may raise up to $150 million in total, includes participation from existing and new investors. The funds will support the company's hypergrowth strategy and investment in novel technologies and clinical evidence.
Additionally, Shacey Petrovic has been appointed to the newly created position of Vice Chair of the Board of Directors. Petrovic, who joined the board in 2023, will focus on scaling strategies to bring life-changing technologies to more patients. She previously served as President and CEO of Insulet and currently sits on the boards of Exact Sciences (EXAS), Ambu A/S, and Axena Health.
CereVasc, a clinical-stage medical device company, has appointed Shlomi Nachman and Timothy Scannell to its Board of Directors, effective July 11, 2024. Nachman, former Company Group Chairman at Johnson & Johnson's Medical Devices sector, brings over 25 years of industry experience. Scannell, former President and COO of Stryker , has more than 30 years of leadership experience in medical technology.
Dan Levangie, CereVasc's Chairman and CEO, expressed excitement about leveraging their expertise to bring the eShunt System to market. Both appointees have extensive backgrounds in medical devices and neurovascular fields, with Nachman's experience in cardiovascular solutions and Scannell's success in MedSurg & Neurotechnology businesses.
Insulet (NASDAQ: PODD), a leader in tubeless insulin pump technology, will release its financial results for Q2 2024 on August 8, 2024, after the market closes. A conference call will follow at 4:30 p.m. ET, accessible via the Investor Relations section of the company's website or by phone. Insulet's flagship product, the Omnipod® platform, offers innovative insulin delivery solutions, including the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors for simplified diabetes management.
Insulet (NASDAQ: PODD) announced positive results from its SECURE-T2D pivotal trial at the ADA 84th Scientific Sessions. The trial, the largest and most diverse study of automated insulin delivery (AID) in type 2 diabetes, highlighted significant improvements with the Omnipod 5 system. The results showed a 0.8% reduction in HbA1c overall, with a 2.1% decrease for those with baseline HbA1c ≥9.0%. Time in range increased by 20%, and total daily insulin dose decreased by 23 U/day. There were no significant hypoglycemia risks. The study included 305 participants, with 24% Black and 22% Hispanic representation, aiming for FDA approval for use in type 2 diabetes by early 2025.
Insulet has announced the full commercial launch of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) in the UK and the Netherlands. This system, compatible with Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitors, is available for individuals aged two and older with type 1 diabetes. Omnipod 5 is the first tubeless automated insulin delivery system integrated with both leading CGM sensor brands. It offers proactive glucose control, is waterproof, and aims to provide ease of use with demonstrated clinical results such as lower A1c levels and improved time in range. Patrick Crannell, Insulet's Senior VP, highlights the system's ability to allow users to choose their preferred CGM sensor, potentially benefiting thousands more people with diabetes.
Professor Partha S. Kar from NHS England emphasized the system's capacity to significantly simplify diabetes management. Clinical results have shown strong performance in maintaining glucose levels within the desired range while minimizing hypoglycemia instances.
Insulet (NASDAQ: PODD), a leader in tubeless insulin pump technology, announced the launch of its Omnipod 5 Automated Insulin Delivery System in France, now available for people aged two and older and compatible with the Dexcom G6 CGM. The French National Authority for Health has granted reimbursement status for the system.
In the U.S., Insulet has commenced the full commercial launch of Omnipod 5 with Dexcom G7 integration, offering users a new Pod compatible with both Dexcom G6 and G7 sensors. Additionally, the Omnipod 5 App for iPhone has begun a market release, initially integrating with Dexcom G6, with future updates to include Dexcom G7 compatibility.
These milestones reflect Insulet's commitment to expanding access to its innovative diabetes management technology globally.
Insulet (NASDAQ: PODD) announced that its management will present at the Jefferies Global Healthcare Conference in New York City on June 6, 2024, at 9:00 a.m. ET. The presentation will be accessible via a live audio webcast on the company's investor relations site, with a replay available post-event.
Insulet is renowned for its Omnipod® product platform, a tubeless insulin pump technology aimed at simplifying life for people with diabetes. The Omnipod Insulin Management System offers up to three days of non-stop insulin delivery without needle handling. Their latest innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor and can be controlled via smartphone or the Omnipod 5 Controller. Insulet is also exploring the use of its Omnipod technology for non-insulin subcutaneous drug delivery.
Insulet (NASDAQ: PODD) reported a 23% year-over-year revenue increase in the first quarter of 2024, with total revenue reaching $441.7 million. The Company exceeded its guidance range due to revenue outperformance across all product lines. Gross margin increased to 69.5%, operating income rose to $56.9 million, and net income reached $51.5 million. Insulet also achieved strong new customer starts, expanded market share globally, and launched new products like Omnipod 5 integrated with Dexcom's G7 sensor. The company is raising its full-year revenue and operating margin guidance for 2024.
Insulet (NASDAQ: PODD) released its 2023 Sustainability Report highlighting achievements in environmental, social, and governance areas. The report focuses on product accessibility, responsible growth, affordability, resilient operations, and sustainable product innovation. Insulet reached 425,000 active global customers, expanded financial assistance programs, generated renewable energy, reduced waste, and enhanced product sustainability. The company conducted a comprehensive double materiality assessment to prioritize initiatives and ensure operational resilience.
FAQ
What is the main product of Insulet Corporation?
Where is Insulet Corporation headquartered?
When was Insulet Corporation founded?
How does the Omnipod system benefit users compared to multiple daily insulin injections (MDI)?
How many people worldwide use the Omnipod system?
What makes the Omnipod system different from conventional insulin pumps?
When was the Omnipod system approved by the FDA?
How does the Omnipod system enhance user convenience?
What is Insulet Corporation's mission?
What are Insulet Corporation's recent achievements?
